Cancer Chemotherapy and Pharmacology

, Volume 59, Issue 6, pp 825–837

Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer

  • Jan H. Beumer
  • Jeany M. Rademaker-Lakhai
  • Hilde Rosing
  • Michel J. X. Hillebrand
  • Tessa M. Bosch
  • Luis Lopez-Lazaro
  • Jan H. M. Schellens
  • Jos H. Beijnen
Original Article

Abstract

Purpose

Trabectedin (ET-743, Yondelis™) is a novel anti-cancer drug currently undergoing phase II–III evaluation, that has shown remarkable activity in pre-treated patients with soft tissue sarcoma. Despite extensive pharmacokinetic studies, the human disposition and metabolism of trabectedin remain largely unknown. We aimed to determine the metabolic profile of trabectedin and to identify its metabolites in humans.

Methods

We analysed urine and faeces (the major excretory route) from eight cancer patients after a 3 or 24 h intravenous administration of [14C]trabectedin. Using liquid chromatography with tandem quadrupole mass spectrometric detection (LC-MS/MS) and radiochromatography with off-line radioactivity detection by liquid scintillation counting (LC-LSC), we characterised the metabolic profile in 0–24 h urine and 0–120 h faeces.

Results

By radiochromatography, a large number of trabectedin metabolites were detected. Incubation with β-glucuronidase indicated the presence of a glucuronide metabolite in urine. Trabectedin, ET-745, ET-759A, ETM-259, ETM-217 (all available as reference compounds) and a proposed new metabolite coined ET-731 were detected using LC-MS/MS. The inter-individual differences in radiochromatographic profiles were small and did not correlate with polymorphisms in drug-metabolising enzymes (CYP2C9, 2C19, 2D6, 2E1, 3A4, GST-M1, P1, T1 and UGT1A1 2B15) as determined by genotyping.

Conclusions

Trabectedin is metabolically converted to a large number of compounds that are excreted in both urine and faeces. In urine and faeces we have confirmed the presence of trabectedin, ET-745, ET-759A, ETM-259, ETM-217 and ETM-204. In addition we have identified a putative new metabolite designated ET-731. Future studies should be aimed at further identification of possible metabolites and assessment of their activity.

Keywords

Trabectedin Metabolism Excretion Genotyping Human 

References

  1. 1.
    Beumer JH, Rademaker-Lakhai JM, Rosing H, Lopez-Lazaro L, Beijnen JH, Schellens JH (2005) Invest New Drugs 23:429–436PubMedCrossRefGoogle Scholar
  2. 2.
    Beumer JH, Schellens JH, Beijnen JH (2005) Pharmacol Res 51:391–398PubMedGoogle Scholar
  3. 3.
    Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J (1990) J Clin Microbiol 28:495–503PubMedGoogle Scholar
  4. 4.
    Brandon EF, Sparidans RW, Guijt KJ, Lowenthal S, Meijerman I, Beijnen JH, Schellens JH (2006) Invest New Drugs 24(1):3–14PubMedCrossRefGoogle Scholar
  5. 5.
    Coleman JP, White WB, Egestad B, Sjovall J, Hylemon PB (1987) J Biol Chem 262:4701–4707PubMedGoogle Scholar
  6. 6.
    D’Incalci M, Jimeno J (2003) Expert Opin Investig Drugs 12:1843–1853PubMedCrossRefGoogle Scholar
  7. 7.
    Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD (2005) J Clin Oncol 23:5484–5492PubMedCrossRefGoogle Scholar
  8. 8.
    Goldstein JA, Blaisdell J (1996) Meth Enzymol 272:210–218PubMedGoogle Scholar
  9. 9.
    Grasten SM, Juntunen KS, Poutanen KS, Gylling HK, Miettinen TA, Mykkanen HM (2000) J Nutr 130:2215–2221PubMedGoogle Scholar
  10. 10.
    Huang CS, Luo GA, Huang ML, Yu SC, Yang SS (2000) Pharmacogenetics 10:539–544PubMedCrossRefGoogle Scholar
  11. 11.
    Jeronimo C, Varzim G, Henrique R, Oliveira J, Bento MJ, Silva C, Lopes C, Sidransky D (2002) Cancer Epidemiol Biomarkers Prev 11:445–450PubMedGoogle Scholar
  12. 12.
    Jin S, Gorfajn B, Faircloth G, Scotto KW (2000) Proc Natl Acad Sci USA 97:6775–6779PubMedCrossRefGoogle Scholar
  13. 13.
    Kanzaki A, Takebayashi Y, Ren XQ, Miyashita H, Mori S, Akiyama S, Pommier Y (2002) Mol Cancer Ther 1:1327–1334PubMedGoogle Scholar
  14. 14.
    van Kesteren C, de Vooght MM, Lopez-Lazaro L, Mathot RA, Schellens JHM, Jimeno JM, Beijnen JH (2003) Anticancer Drugs 14:487–502PubMedCrossRefGoogle Scholar
  15. 15.
    Kuffel MJ, Reid JM, Ames MM (1997) Proc Am Assoc Cancer Res 38:4003Google Scholar
  16. 16.
    MacLeod SL, Nowell S, Plaxco J, Lang NP (2000) Ann Surg Oncol 7:777–782PubMedCrossRefGoogle Scholar
  17. 17.
    Minuzzo M, Marchini S, Broggini M, Faircloth G, D’Incalci M, Mantovani R (2000) Proc Natl Acad Sci USA 97:6780–6784PubMedCrossRefGoogle Scholar
  18. 18.
    Moore BM, Seaman FC, Wheelhouse RT, Hurley LH (1998) J Am Chem Soc 120:2490–2491CrossRefGoogle Scholar
  19. 19.
    Morales JJ (1999) Marine natural products chemistry of a Caribbean tunicate and a Palau sponge. Thesis, University of Illinois, UrbanaGoogle Scholar
  20. 20.
    Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW (1996) Biochemistry 35:13303–13309PubMedCrossRefGoogle Scholar
  21. 21.
    Rosing H, Hillebrand MJ, Jimeno JM, Gomez A, Floriano P, Faircloth G, Henrar RE, Vermorken JB, Cvitkovic E, Bult A, Beijnen JH (1998) J Mass Spectrom 33:1134–1140PubMedCrossRefGoogle Scholar
  22. 22.
    Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ (2000) Clin Pharmacol Ther 67:48–56PubMedCrossRefGoogle Scholar
  23. 23.
    van Schaik RH, van der Heiden I, van den Anker JN, Lindemans J (2002) Clin Chem 48:1668–1671PubMedGoogle Scholar
  24. 24.
    Schur BC, Bjerke J, Nuwayhid N, Wong SH (2001) Clin Chim Acta 308:25–31PubMedCrossRefGoogle Scholar
  25. 25.
    Sparidans RW, Rosing H, Hillebrand MJ, Lopez-Lazaro L, Jimeno JM, Manzanares I, van Kesteren C, Cvitkovic E, van Oosterom AT, Schellens JHM, Beijnen JH (2001) Anticancer Drugs 12:653–666PubMedCrossRefGoogle Scholar
  26. 26.
    Sreelekha TT, Ramadas K, Pandey M, Thomas G, Nalinakumari KR, Pillai MR (2001) Oral Oncol 37:593–598PubMedCrossRefGoogle Scholar
  27. 27.
    Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA (1996) Pharmacogenetics 6:341–349PubMedCrossRefGoogle Scholar
  28. 28.
    Verweij J (2005) J Clin Oncol 23:5420–5423PubMedCrossRefGoogle Scholar
  29. 29.
    Villalona-Calero MA, Eckhardt SG, Weiss G, Hidalgo M, Beijnen JH, van Kesteren C, Rosing H, Campbell E, Kraynak M, Lopez-Lazaro L, Guzman C, Von Hoff DD, Jimeno J, Rowinsky EK (2002) Clin Cancer Res 8:75–85PubMedGoogle Scholar
  30. 30.
    Wu X, Shi H, Jiang H, Kemp B, Hong WK, Delclos GL, Spitz MR (1997) Carcinogenesis 18:967–973PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Jan H. Beumer
    • 1
    • 5
  • Jeany M. Rademaker-Lakhai
    • 2
  • Hilde Rosing
    • 1
  • Michel J. X. Hillebrand
    • 1
  • Tessa M. Bosch
    • 1
  • Luis Lopez-Lazaro
    • 3
  • Jan H. M. Schellens
    • 2
    • 4
  • Jos H. Beijnen
    • 1
    • 4
  1. 1.Department of Pharmacy and PharmacologySlotervaart Hospital/The Netherlands Cancer InstituteAmsterdamThe Netherlands
  2. 2.Departments of Medical Oncology and Experimental TherapyAntoni van Leeuwenhoek Hospital/The Netherlands Cancer InstituteAmsterdamThe Netherlands
  3. 3.PharmaMar, Human Pharmacology, Colmenar ViejoMadridSpain
  4. 4.Department of Biomedical Analysis, Division of Drug Toxicology, Faculty of Pharmaceutical SciencesUtrecht UniversityUtrechtThe Netherlands
  5. 5.The Hillman Cancer Center, Research Pavilion, G.27d, 5117 Centre AvenuePittsburghUSA

Personalised recommendations